The Europe blood screening market size was valued at USD 648.5 million in 2017. It is expected to witness a CAGR of 7.7% during the forecast period. The rising number of blood transfusion procedures is expected to be the major factor boosting the market growth. The rise in the number of complex surgeries performed, such as chemotherapy, heart surgery, and organ transplant, which require a large number of blood samples is also likely to have a positive impact on the market.
Moreover, increasing awareness about safe blood transfusion and rising incidence of infectious diseases are projected to augment the market development in the coming years. Stringent government regulations regarding the screening of all donors and donated blood for patient safety are anticipated to further propel the market growth.
Such guidelines regarding the transfusion services provide a regulatory framework for the manufacturers of blood transfusion reagents. European countries have mandated blood screening for HIV, HBV, HCV, parvovirus 19, and other viruses. The blood transfusion services in Germany are regulated by the International Red Cross, the Code of International Society of Blood Transfusion, and the German Transfusion Act.
In France, the French Blood Establishment (EFS) regulates the collection, preparation, testing, and distribution of labile blood products. In Italy, the National Blood Centre (NBC), a division of health ministry, is responsible for the coordination of technical and scientific control of the blood system.
Based on technology, the market is classified as Nucleic Acid Amplification Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Next-Generation Sequencing (NGS), and western blotting. NAT segment led the market, in terms of revenue share, in 2017. NAT was initially introduced in six European countries including France, Germany, Spain, Italy, U.K., and Switzerland between 1999 and 2001. It is the first mandatory plasma screening test to detect Hepatitis C Virus (HCV).
The demand for ELISA, particularly from developing countries, is on the rise owing to low screening costs, wide application areas, and rising prevalence of chronic infectious diseases. It is majorly used for the detection of HIV, HCV, and HBV and is recommended for routine use in the European region.
Based on the product, the Europe blood screening market is segmented into reagents and instruments. Reagents segment led the market in 2017. Reagents are necessary for ELISA, western blotting, and NAT testing. Rising adoption of these tests contributed to the high demand for reagents. Instruments are expected to witness lesser demand than reagents as they are a one-time investment for blood testing due to their high costs and long shelf-life.
Geographically, the market has been classified into the U.K., Germany, France, Italy, and Spain. In 2017, Germany held the largest market share and is expected to retain its position throughout the forecast period. The regional market is expected to grow due to a rise in awareness about blood donation.
According to the WHO, blood donation increased from 3.4% in 2008 to 3.6% in 2010. Around 2 million people donate blood regularly in Germany. In France, NAT has been voluntarily implemented to increase the safety specific to non-enveloped viruses, such as Hepatitis A Virus (HAV) and Parvovirus B19 (B19V).
Some of the major companies in the market are Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GMBH; Grifols, S.A.; Becton, Dickinson, and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp. Most of the manufacturers focus on new technology launch and M&A activities for business expansion.
For instance, Grifols acquired Hologic’s unit, which is engaged in the manufacturing and R&D of assays and instruments based on NAT technology for donor screening. The sales of Procleix NAT Solutions from this acquisition became the leading source of revenue for the diagnostic division.
Attribute |
Details |
The base year for estimation |
2017 |
Actual estimates/Historical data |
2014 - 2017 |
Forecast period |
2018 - 2025 |
Market representation |
Revenue in USD Million and CAGR from 2018 to 2025 |
Regional scope |
Europe |
Country scope |
U.K., Germany, France, Italy, and Spain |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors & trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue and volume growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the Europe blood screening market report based on technology, product, and region:
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Nucleic Acid Amplification Test (NAT)
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassay (CLIA)
Next-Generation Sequencing (NGS)
Western Blotting
Product Outlook (Revenue, USD Million, 2014 - 2025)
Reagents
Instruments
Country Outlook (Revenue, USD Million, 2014 - 2025)
U.K.
Germany
France
Italy
Spain
b. The Europe blood screening market size was estimated at USD 684.5 million in 2019 and is expected to reach USD 755.3 million in 2020.
b. The Europe blood screening market is expected to grow at a compound annual growth rate of 7.7% from 2018 to 2025 to reach USD 1.2 billion by 2025.
b. Germany dominated the Europe blood screening market with a share of 28.9% in 2019. This is attributable to rise in awareness about blood donation in countries such as U.K., Germany, France, Italy, and Spain.
b. Some key players operating in the Europe blood screening market include Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GMBH; Grifols, S.A.; Becton, Dickinson and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp.
b. Key factors that are driving the market growth include rising number of blood transfusion procedures and rise in the number of complex surgeries performed, such as chemotherapy, heart surgery, and organ transplant, which require a large amount of blood samples.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.